
Copyright © 2015 The Authors

http://eprints.gla.ac.uk/102708/

Deposited on: 17 February 2015
Reply

Tamer Abdelrahman¹, Joseph Hughes¹, Janice Main², John McLauchlan¹, Mark Thursz², Emma Thomson¹,²

¹MRC University of Glasgow Centre for Virus Research, 8 Church Street Glasgow, UK G11 5JR
²Department of Medicine, Imperial College NHS Trust, Praed Street, London, UK W2 1NY

Tamer Abdelrahman tamer.abdelrahman@glasgow.ac.uk
Joseph Hughes joseph.hughes@glasgow.ac.uk
Janice Main j.main@imperial.ac.uk
John McLauchlan john.mclauchlan@glasgow.ac.uk
Mark Thursz m.thursz@imperial.ac.uk
Emma Thomson emma.thomson@glasgow.ac.uk

Corresponding author

Dr Tamer Abdelrahman
Clinical Research Fellow
MRC-University of Glasgow Centre for Virus Research
8 Church Street, Glasgow G11 5JR, UK
Office: 0141 330 6257

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.27393
In response to Martin et al:

We agree with Martin et al that, as yet, late recurrence of hepatitis C following treatment has not been studied in this highly-exposed group of patients. To clarify the point made in our study “Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment”,(1) the majority of cases labelled as HCV reinfection within the 24 week window post-treatment are likely to represent viral rebound rather than reinfection, even in the presence of a switch in genotype or subtype. In the absence of detailed sequencing data, it indeed seems likely that patients with recurrent HCV infection have a high rate of reinfection,(2) although there is a need to carry out an appropriately designed study to confirm this as some studies in other highly exposed cohorts have shown that relapse is associated with recrudescence of similar strains, others have lacked analysis of paired samples and none have employed a next generation sequencing approach.(3, 4) In the meantime, the proposed adjustment to the reinfection rate following removal of the 7% of patients that relapsed within the 24 week post-treatment would seem entirely appropriate.(5, 6) We also agree that retreatment is indicated in patients with recurrent HCV infection. The role of the emergence of resistant variants will be of particular interest as DAAs are rolled out, in particular when interferon-free regimens are used, as interferon resistance is likely to be heavily influenced by the host response and is unlikely to occur solely due to mutations within the viral genome.